Indegene Share Price

NSE
INDGN •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Indegene
Indegene Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Indegene Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
-9.1
Dividend yield 1yr %
0

Indegene Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Indegene Quarterly Revenue

Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
755.6 Cr
720.4 Cr
686.8 Cr
676.5 Cr
673 Cr

Indegene Yearly Revenue

Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
2946.5 Cr
2665.9 Cr
2364.1 Cr
1690.5 Cr
996.92 Cr

Indegene Quarterly Net Profit/Loss

Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
117.6 Cr
109.7 Cr
91.7 Cr
87.7 Cr
94.8 Cr

Indegene Yearly Net Profit/Loss

Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
406.7 Cr
336.7 Cr
266.1 Cr
162.82 Cr
185.88 Cr
Indegene Result Highlights
  • Indegene Ltd reported a 8.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a - of -.

  • Its expenses for the quarter were down by 7.6% QoQ and - - YoY.

  • The net profit decreased 13.6% QoQ and - - YoY.

  • The earnings per share (EPS) of Indegene Ltd stood at 4.2 during Q4FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Indegene shareholding Pattern

Foreign Institutions
5.2%
Mutual Funds
2.6%
Domestic Institutions
5%
Public
89.8%
Foreign Institutions
5%
Mutual Funds
1.6%
Domestic Institutions
4%
Public
91%
Foreign Institutions
4.8%
Mutual Funds
1.6%
Domestic Institutions
3.2%
Public
92%
Foreign Institutions
3.8%
Mutual Funds
2.3%
Domestic Institutions
3.8%
Public
92.4%

Indegene Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
4
Bearish Moving Averages
12
5Day EMA
566.70
10Day EMA
567.40
12Day EMA
567.00
20Day EMA
564.40
26Day EMA
563.30
50Day EMA
566.90
100Day EMA
580.20
200Day EMA
590.20
5Day SMA
569.10
10Day SMA
571.20
20Day SMA
567.50
30Day SMA
556.60
50Day SMA
553.50
100Day SMA
584.60
150Day SMA
613.20
200Day SMA
609.10
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
200787 Rs
432493 Rs
Week Rs
136587 Rs
266594 Rs
Month Rs
134297 Rs
274829 Rs
Resistance & Support
565.82
Pivot
Resistance
First Resistance
577.13
Second Resistance
596.17
Third Resistance
607.48
Support
First Support
546.78
Second support
535.47
Third Support
516.43
Relative Strength Index
47.95
Money Flow Index
46.21
MACD
3.64
MACD Signal
4.07
Average True Range
22.45
Average Directional Index
14
Rate of Change (21)
-0.48
Rate of Change (125)
-18.29

Indegene Latest News

29 APR 2025 | Tuesday

Indegene Ltd - 544172 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

29 APR 2025 | Tuesday

Indegene Results Earnings Call for Q4FY25 & Full Year

28 APR 2025 | Monday

Indegene Ltd - 544172 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

View More

Indegene Company background

Founded in: 1998
Indegene Limited was incorporated as Indegene Lifesystems Private Limited at Ahmedabad, Gujarat, as a Private Limited Company, dated October 16, 1998 at Ahmedabad. Subsequently, name of the Company was changed to Indegene Private Limited and a fresh Certificate of Incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. Thereafter, Company converted to a Public Company with change in name to Indegene Limited on November 17, 2022.The Company is a global provider of solutions consisting of analytics, technology and commercial, medical, regulatory and safety services to life science and healthcare organizations. It provide digitalled commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products.Their Enterprise Commercial Solutions (ECS) involve assisting life sciences companies with their digital marketing operations. Omnichannel Activation solutions help life sciences companies leverage a digital first approach for optimizing the lastmile promotion of biopharmaceutical products and medical devices to HCPs across multiple channels. Under Enterprise Medical Solutions, the Company establish centers of excellence (CoEs) to consolidate large scale regulatory and medical operations for their clients.Apart from these, the Company offer Enterprise Clinical Solutions and consultancy services, which help drive efficiencies in the drug discovery and clinical trial operations of life sciences companies. It bring in their expertise in data management and analyticsin helping biopharmaceutical companies seamlessly handle and analyze multiple sources of data during clinical trials and build a case for regulatory approvals.In 2016, the Company acquired Encima Group, Inc. in the United States, a company which provided marketing analytics and campaign execution solutions to several large life sciences companies. In 2019, it acquired a minority stake in DT Associates Research and Consulting Services Limited, a digital transformation and client experience consulting firm in UK, to expand their strategic consulting capabilities. In December 2020, it acquired a majority stake in DT Associates Limited.On 8 December, 2021 the Company has demerged its commercial software business pursuant to a Scheme of Arrangement for transfer of the Demerged Business to OT Services India Private Limited (Resulting Company), approved by the National Company Law Tribunal, Bengaluru Bench with Appointed Date, i.e., October 1, 2020, which became effective on December 30, 2021.The Company acquired Cult Health, a fullservice healthcare marketing agency for several life sciences brands, through its subsidiary, ILSL Holdings, Inc. on October 12, 2022.The Company launched Invisage, an AIenabled hybrid omnichannel sales and marketing platform in 2023. The Company made a public issue of 40,766,550 Equity Shares of face value of Rs 2 each by raising funds aggregating to Rs. 1842 Crore comprising a fresh issue of 16,833,818 Equity Shares aggregating to Rs. 760 Crore and 23,932,732 Equity Shares aggregating to Rs 1082 Crore through Offer for Sale in May, 2024.In 2024, the Company acquired a controlling stake in Trilogy Writing Consulting GmbH.
Read More

Indegene FAQs

Indegene share price is ₹563.15 in NSE and ₹563.4 in BSE as on 30/4/2025.

Indegene share price in the past 1-year return was 0. The Indegene share hit a 1-year low of Rs. 470.1 and a 1-year high of Rs. 736.3.

The market cap of Indegene is Rs. 13394.84 Cr. as of 30/4/2025.

The PE ratios of Indegene is 73.91 as of 30/4/2025.

The PB ratios of Indegene is 7.09 as of 30/4/2025

The Mutual Fund Shareholding in Indegene was 2.65% at the end of 30/4/2025.

You can easily buy Indegene shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Indegene stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -